Analyst Price Targets — REPL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 11:49 am | — | Piper Sandler | $14.00 | $7.00 | TheFly | Replimune price target raised to $14 from $13 at Piper Sandler |
| November 3, 2025 9:23 am | Evan Seigerman | BMO Capital | $11.00 | $9.73 | TheFly | Replimune upgraded to Market Perform from Underperform at BMO Capital |
| October 27, 2025 10:17 am | — | H.C. Wainwright | $12.00 | $8.80 | TheFly | Replimune upgraded to Buy from Neutral at H.C. Wainwright |
| October 20, 2025 1:05 pm | — | Wedbush | $18.00 | $9.15 | TheFly | Wedbush upgrades Replimune to Outperform amid second BLA review |
| January 22, 2025 2:41 pm | Evan Seigerman | BMO Capital | $27.00 | $13.09 | TheFly | Replimune price target raised to $27 from $18 at BMO Capital |
| December 3, 2024 8:58 pm | Roger Song | Jefferies | $19.00 | $14.48 | StreetInsider | Replimune Group (REPL) PT Raised to $19 at Jefferies |
| June 7, 2024 6:07 am | Robert Burns | H.C. Wainwright | $17.00 | $7.11 | TheFly | Replimune Group price target raised to $17 from $12 at H.C. Wainwright |
| June 4, 2024 9:51 am | Peter Lawson | Barclays | $13.00 | $5.37 | StreetInsider | Barclays Reiterates Overweight Rating on Replimune Group (REPL) |
| May 17, 2024 7:40 am | Evan Seigerman | BMO Capital | $14.00 | $6.85 | StreetInsider | BMO Capital Reiterates Outperform Rating on Replimune Group (REPL) |
| December 12, 2022 7:42 am | — | BMO Capital | $70.00 | $25.00 | Benzinga | BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $70 |
Latest News for REPL
Replimune Group Inc. (NASDAQ: REPL) on Friday received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application.
REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.
Replimune Group (NASDAQ:REPL) shares fell roughly 63% following the company's disclosure that it received a Complete Response Letter (CRL) from the US Food and Drug Administration, effectively blocking the approval of its lead melanoma therapy RP1 in combination with nivolumab. The decision represents a significant setback for the biotechnology company, which had been seeking approval based on data from its IGNYTE…
Philip Astley-Sparke, executive chairman and co-founder at Replimune, joins ‘Squawk on the Street' to discuss the company's next steps after the FDA denied its melanoma drug.
Top insights from the latest market news from Monday, April 13, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for REPL.
U.S. House Trading
No House trades found for REPL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.